Coronary disease & ACS

Stress Cardiac Magnetic Resonance Ischemia Burden and Cardiovascular Events: Post-Hoc Analysis From the ISCHEMIA Trial

JACC Cardiovasc ImagingPublished Secondary analysis of the ISCHEMIA randomised trial

Authors' conclusion

Ischemia severity by CMR had a stronger association with all ISCHEMIA trial endpoints compared with SPECT/echo.

Study context

Population
Patients with coronary disease and site-interpreted moderate to severe ischemia in the ISCHEMIA trial3,909 randomized
Participants
313 vs 5,627
Comparison
Stress cardiac magnetic resonance (CMR) vs SPECT/echo
  • CMRn = 313
  • SPECT/echon = 5,627reference
Primary endpoint
CV death, nonfatal MI, or hospitalization for unstable angina, HF, or resuscitated cardiac arrest (trial primary outcome), by ischemia severity
Follow-up
4 years
Methodological detailsMedian follow-up 3.37 years (Q1-Q3: 2.20-4.56 years)
  • Median follow-up 3.37 years (Q1-Q3: 2.20-4.56 years)

Primary result

As reported in the abstract

4-year primary outcome rate by ischemia severity (no/mild, moderate, severe)

No/mild

Moderate

Severe

CMR ischemia severity associated with primary outcome; SPECT/echo ischemia severity was not
P = 0.042

Further findings

Severe ischemia

P < 0.001

Randomized

P < 0.001

Invasive referral and coronary revascularization (conservative management, no/mild ischemia) · 4 years

Invasive referral

Revascularization

CV death/myocardial infarction (MI) and nonfatal MI by CMR ischemia severity · 4 years

CMR ischemia severity associated with CV death/MI
P = 0.041
CMR ischemia severity associated with nonfatal MI
P = 0.03
SPECT/echo ischemia severity not associated

Original publication

Stress Cardiac Magnetic Resonance Ischemia Burden and Cardiovascular Events: Post-Hoc Analysis From the ISCHEMIA Trial. JACC Cardiovasc Imaging. Published 5 December 2025. doi:10.1016/j.jcmg.2025.10.015

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.